- Novartis (NVS) is in advanced negotiations to acquire Israeli stem-cell treatments developer Gamida-Cell for up to $600M, Israel's Globes reports.
- Novartis would pay hundreds of millions of dollars up front and the rest in milestones for the company, which develops therapies for a variety of conditions, including blood cancers and solid tumors.
- Gamida shareholders Elbit Medical and Clal Biotechnology confirmed that a sizable offer had been made, but didn't disclose the suitor. Another investor is Teva (TEVA).
- While talks are advanced, Gamida hasn't ruled out the prospect of an IPO in New York instead, although the firm's valuation in a listing would be lower.
From other sites
at Zacks.com (Mon, 4:14PM)
at Zacks.com (Mar 18, 2015)
at MarketWatch.com (Mar 6, 2015)
at Zacks.com (Mar 5, 2015)
at Nasdaq.com (Feb 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs